Dr. Shayman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 East Medical Center Dr
University Hospital - Im Nephrology Inpatient
Ann Arbor, MI 48109Phone+1 734-888-2871
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Nephrology, 1985 - 1985- Washington University/B-JH/SLCH ConsortiumFellowship, Nephrology, 1983 - 1984
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1980 - 1983
- Washington University in St. Louis School of MedicineClass of 1980
Certifications & Licensure
MI State Medical License 1986 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1994
- Fellow (ASNF) American Society of Nephrology
Publications & Presentations
PubMed
- 206 citationsImproved inhibitors of glucosylceramide synthase.Lihsueh Lee, Akira Abe, James A. Shayman
The Journal of Biological Chemistry. 1999-05-21 - 124 citationsA specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern, John J. Fung, Svetlana Komarnitsky, Craig Siegel, Wei-Lien Chuang
Molecular Genetics and Metabolism. 2007-07-01 - 18 citationsDissociation of globotriaosylceramide and impaired endothelial function in α-galactosidase-A deficient EA.hy926 cells.Nayiri M. Kaissarian, Justin J Kang, Liming Shu, Maria J. Ferraz, Johannes M. F. G. Aerts
Molecular Genetics and Metabolism. 2018-11-02
Press Mentions
Protalix’s Phase III Asset for Fabry Could Struggle to Demonstrate Superiority over Fabrazyme but Immunogenicity Benefits Support Regulatory Chances, Experts SayFebruary 5th, 2021
Sanofi Pivotal Trial to Target Driver of Cyst Growth in PKDNovember 12th, 2018
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis from the HALT-PKD TrialsJanuary 4th, 2018
Grant Support
- Lysosomal Phospholipase A2 In Autoimmune DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2012
- The Pharmacological Treatment Of Fabry DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2012
- The Pharmacologic Treatment Of Fabry DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2008
- Glycosphingolipids In Diabetes MellitusNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1999
- Glycosphingolipid And Renal CarcinomaNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1997
- Sphingolipids And Polycystic Kidney DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1997
- Renal Polyol MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1990–1994
- Peptide Hormone Stimulated Inositol MetabolismNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1989
- Peptide Hormone Stimulated Inositol MetabolismNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
